Metabolised by CYP3A4 but no clinical data pointing to CYP-induction. Two references stating non-porphyrinogenicity.
Chemical description
Selective 5-HT-antagonist used as antiemetic for postoperative nausea and nausea under chemotherapy, 4-32 mg/d given perorally or intravenously. Hydroxylated and conjugated to glucuronic acid and sulfate via CYP 3A4. No instances of clinically significant CYP-induction observed.
Ipnet drug reports
Uneventful use reported in 12 patients with acute porphyria.
Similar drugs
Explore alternative drugs in similar therapeutic classes
A04A /
A04AA or
go back.
References
#
Citation details
PubMed ID
1.
Ondansetron in a patient with porphyria.
De Wet M, Jooste R, et al. S Afr Med J. 1992 Dec; 82(6):480.